Results 31 to 40 of about 8,768 (188)

Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder. [PDF]

Pulm Circ
ABSTRACT Pulmonary arterial hypertension (PAH) is a life‐threatening disease of the pulmonary arteries. Progressively increasing pulmonary artery pressure may lead to fatal failure of the right ventricle, necessitating aggressive drug treatment. Sotatercept, a novel drug for PAH‐targeted therapy, shows promising results in clinical trials. Nevertheless,
Schneijdenberg JW, van den Bosch AE, Kap ME, Kauling RM, Chandoesing PP, van den Toorn LM, Mathot BJ, Koudstaal T, Boomars KA.   +8 more
europepmc   +2 more sources

Lifesaving Compassionate-Use of Sotatercept in a 12-Year-old With Idiopathic Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
ABSTRACT Pediatric idiopathic pulmonary arterial hypertension (IPAH) refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited. We describe a 12‐year‐old girl with end‐stage IPAH who developed acute decompensated right heart failure despite triple combination therapy, including high ...
Pelczar-Płachta W, Surmacz R, Bobkowski W.   +2 more
europepmc   +2 more sources

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

Drug Delivery, 2018
Pulmonary arterial hypertension (PAH) can be relieved by pharmacological interventions, especially the targeted drug, which is classified into endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostaglandin I2, soluble guanylate cyclase ...
Sumei Wang, Miao Yu, Xiangchun Zheng, Shangjuan Dong   +3 more
doaj   +1 more source

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

BMC Pulmonary Medicine, 2017
Background No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung.
Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma   +2 more
doaj   +1 more source

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor

Infectious Disease Reports, 2015
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli, Maria P. Cicini, Leopoldo P. Pucillo, Nicola Petrosillo   +7 more
doaj   +1 more source

Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict drug induced hepatotoxicity

, 2013
Human hepatocytes are the gold standard for toxicological studies but they have several drawbacks, like scarce availability, high inter-individual variability, a short lifetime, which limits their applicability.
Jemnitz, Katalin, Monika Szabo, Katalin Jemnitz, Veres, Zsuzsa, Zsuzsa Veres, Baranyai, Zsolt, Zsolt Baranyai, Szabo, Monika, Ferenc Jakab, Jakab, Ferenc   +9 more
core   +1 more source

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension

, 2009
Kari E Roberts, Ioana R PrestonPulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USAAbstract: Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH).
Kari Roberts, Kari E Roberts, Ioana Preston, Ioana R Preston   +3 more
core   +1 more source

219. Tratamiento con bosentán en pacientes pre-fontan con presiones elevadas

Cirugía Cardiovascular, 2012
Evaluación inicial de los efectos del bosentán en el tratamiento de pacientes que van a ser sometidos a Fontan con presiones elevadas. Material y métodos: Presentamos una serie de ocho pacientes que recibieron bosentán previo a la derivación cavo ...
J. Otero, C. Merino, J. Casares, M. Conejero, D. Valencia, P. Maiorano, G. Sauchelli, I. Pernia, P. Alados, M.A. García, J. Moya, M. Román, I. Muñoz   +12 more
doaj   +1 more source

Iontophoresis of endothelin receptor antagonists in rats and men. [PDF]

PLoS ONE, 2012
The treatment of scleroderma-related digital ulcers is challenging. The oral endothelin receptor antagonist (ERA) bosentan has been approved but it may induce liver toxicity.
Matthieu Roustit, Sophie Blaise, Claire Arnaud, Marcin Hellmann, Claire Millet, Diane Godin-Ribuot, Boris Dufournet, Jean Boutonnat, Christophe Ribuot, Jean-Luc Cracowski   +9 more
doaj   +1 more source

Maternal and perinatal outcomes of pregnant women with echocardiographically high probability of pulmonary arterial hypertension

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study aimed to describe maternal and perinatal outcomes among pregnant women with echocardiographically high probability of pulmonary arterial hypertension (PAH) managed at a quaternary center and to compare outcomes between women with and without cardiac complications (CC).
Laura Belmont‐Rojo, Rosa Hernandez‐Cruz, Ana Jimena Lopez‐Diaz, Diana Yazmin Copado‐Mendoza, Tirso Rubalcava‐Rubalcava, Mario Isaac Lumbreras‐Marquez, Maria Antonia Pijuan‐Domenech   +6 more
wiley   +1 more source